Fig. 1.

Summary of the diagnostic algorithm following by all subjects recruited to the DIAPHRAGM (Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma) study, including the 315 patients reported here. DIAPHRAGM is a prospective, multi-centre observational study assessing novel potential blood biomarkers of Malignant Pleural Mesothelioma (MPM). DIAPHRAGM incorporates a Magnetic Resonance Imaging (MRI) sub-study allowing correlation between biomarker level and MPM tumour volume.